بسم الله الرحمن الرحيم

∞∞∞

تم رفع هذه الرسالة بواسطة / مني مغربي أحمد

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى مسئولية عن محتوى هذه الرسالة.

ملاحظات: لا يوجد

Integrated Bioanalytical Techniques for Assessment of some Monoclonal Antibodies

Thesis submitted for partial fulfillment of PhD in Pharmaceutical Sciences

"Pharmaceutical Analytical Chemistry"

By

Eman M. Moenes M. Salama

M.Sc. in Pharmaceutical Sciences "Analytical Chemistry" (2018)
Egyptian Drug Authority

Under Supervision of

Prof. Dr. Miriam Farid Ayad

Professor of Pharmaceutical Analytical Chemistry
Faculty of Pharmacy
Ain Shams University

Prof. Dr. Marianne Nebsen Morcos

Professor of Analytical Chemistry
Faculty of Pharmacy
Cairo University

Prof. Dr. Medhat A. Al-Ghobashy

Professor of Analytical Chemistry
Faculty of Pharmacy
Cairo University

Dr. Yossra Ahmed Trabik

lecturer of pharmaceutical Analytical Chemistry
Faculty of Pharmacy
Ain Shams University

Pharmaceutical Analytical Chemistry Department
Faculty of Pharmacy
Ain Shams University

2022

بسم الله الرحمن الرحيم

(قُلْ إِنَّ الْفَضْلَ بِيَدِ اللَّهِ

يُؤْتِيهِ مَن يَشَاءُ وَاللَّهُ وَاسِعٌ عَلِيمٌ)

سورة آل عمران73

Acknowledgment

First and foremost, Thanks to God for giving me the strength, help, endurance, and perseverance to complete this work which would not have been possible without His blessings.

A lot of thanks and appreciations to Dr. Miriam Farid Ayad, Associate Professor of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Ain Shams University for co-operation, generous assistance and support.

Words not enough to express deep thanks to Dr. Marianne Nebsen Morcos, Professor of Analytical Chemistry, Faculty of Pharmacy, Cairo University for continuous support, guidance and endless encouragement.

Sincere gratitude and deepest thanks to my coach Dr. Medhat Ahmed Al-Ghobashy, Professor of Analytical Chemistry, Faculty of Pharmacy, Cairo University for his richest grace, continuous support, encouragement and experience that helped me to accomplish this work. No words could appreciate his guidance throughout my whole life.
Because I owe much to him, Many Thanks!

I want to address a lot of thanks and appreciations to Dr. Yossra Ahmed Trabik, Lecturer of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Ain Shams University for kind supervision, co-operation and support.

I am really grateful to all my colleagues for all good wishes. Last but not least; I would like to thank my whole family whose endless love, sacrificial selfless giving and unceasing prayers have enabled me to complete my work. They have spent their full effort, time, care for encouraging and supporting me spiritually throughout my whole life.

Eman Moenes

2022

List of Abbreviations

4-PL	4-parameter logistics
ADCC	antibody dependent cellular cytotoxicity
BIO-INN	central administration of Biologics, innovator and clinical studies
BSA	bovine serum albumin
CD	circular dichroism
CDR	complementarity determining regions
CEX	cation exchange
CIEF	capillary isoelectric focusing
CLL	chronic lymphocytic leukemia
CZE	capillary zone electrophoresis
DAD	diode array detector
DLS	dynamic light scattering
EC50	Effective concentration
EDA	Egyptian drug authority
ELISA	Enzyme linked immunoassay
Fab	fragment antigen-binding region
Fc	fragment crystallizable region
FDA	food and drug adminstration
HMW	high molecular weight
HPLC	high performance liquid chromatography
HPMC	hydroxy propyl methyl cellulose
Ig	immunoglobulin
ICH	international conference of harmonization

IEX	ion exchange
immunoPET	immuno-positron emission tomography
KDa	kilodalton
LOD	limit of detection
LOQ	limit of quantitation
MALS	multi angel light scattering
mAb	monoclonal antibody
NHL	non-Hodgkin lymphoma
OD	optical density
OBZ	obintuzumab
pAb	polyclonal antibody
PDA	photo diode array
Psi	pound per square inch
PTZ	pertuzumab
RP-HPLC	reversed phase high performance liquid chromatography
RTX	rituximab
RSD	relative standard deviation
SDS-PAGE	sodium dodecyl poly acrylamide gel electrophoresis
SE-HPLC	size exclusion high performance liquid chromatography
TETA	tri ethylene tetramine
TMB	Tetramethyl benzidine
TOC	total organic carbon
WHO	world health organization

List of amino acids abbreviations

Full Name	Abbreviation (3 Letter)	Abbreviation (1 Letter)
Alanine	Ala	A
Arginine	Arg	R
Asparagine	Asn	N
Aspartate	Asp	D
Cysteine	Cys	C
Glutamate	Glu	E
Glutamine	Gln	Q
Glycine	Gly	G
Histidine	His	H
Isoleucine	Ile	I
Leucine	Leu	L
Lysine	Lys	K
Methionine	Met	M
Phenylalanine	Phe	F
Proline	Pro	P
Serine	Ser	S
Threonine	Thr	T
Tryptophane	Try	W
Tyrosine	Tyr	Y
Valine	Val	V

List of figures viii
List of tables xvi
Summary xix

Part I: Introduction

I. Introduction 2
I.1. Biopharmaceuticals 2
I.1.1. Definition and Background 2
I.2. Monoclonal Antibodies 2
I.2.1. Differences between Monoclonal and polyclonal Antibodies 3
I.2.2. Structure of Monoclonal Antibodies 5
I.2.3. Types of Monoclonal Antibodies 7
I.3. Rituximab 9
I.3.1. General Information and Protein Structure 9
I.3.2. Clinical Uses 9
I.4. Biosimilars and Biosimilarity assessment 11
I.4.1. Definition of Biosimilars 11
I.4.2. Biosimilarity Assessment 11
I.5. Glycoengineering in Monoclonal Antibodies development 13
I.6. Obinutuzumab 14
I.6.1. General information and protein structure 14
I.6.2. Clinical uses 14
I.7. Pertuzumab 16
I.7.1. General information and protein structure 16
I.7.2. Clinical uses 17

I.8. Literature Review 17

I.8.1. High-Performance Liquid Chromatography Methods 17

I.8.2. Electrophoresis 28

I.8.3. Spectroscopy 35

I.8.4. Receptor binding assays 39

I.9. Aim of the study 41

Part II: Separation techniques

Section A: SE-HPLC

II.A.1. Introduction 45

II.A.2. Experimental 45

II.A.2.1. Instrumentation 45

II.A.2.2. Chemicals and reagents 46

II.A.2.3. Standards and samples 46

II.A.2.4. Chromatographic conditions 47

II.A.2.5. Calibration and validation 47

II.A.2.6. Stability study 49

II.A.2.7. kinetics of degerdation 50

II.A.2.8. Application to pharmaceutical formulations 50

II.A.2.9. Biosimilarity assessment 51

II.A.3. Results and discussion 51

II.A.3.1. Method optimization 51

II.A.3.2. Method validation and system suitability 52

II.A.3.3. Stability study..... 70

II.A.3.4. kinetics of degerdation 87

II.A.3.5. Application to pharmaceutical formulations..... 90

II.A.3.6. Biosimilarity assessment..... 91

Section B: RP-HPLC

II.B. RP-HPLC..... 94

II.B.1. Introduction..... 94

II.B.2. Experimental..... 94

II.B.2.1. Instrumentation 94

II.B.2.2. Chemicals and reagents..... 94

II.B.2.3. Standards and samples 95

II.B.2.4. Chromatographic conditions..... 95

II.B.2.5. Calibration and validation 96

II.B.2.6. Stability study..... 98

II.B.2.7. kinetics of degerdation 98

II.B.2.8. Application to pharmaceutical formulations..... 98

II.B.2.9. Biosimilarity assessment..... 99

II.B.3. Results and discussion 99

II.B.3.1. Method optimization 99

II.B.3.2. Method validation and system suitability 101

II.B.3.3. Stability study 117

II.B.3.4. kinetics of degerdation 122

II.B.3.5. Application to pharmaceutical formulations 124

II.B.3.6. Biosimilarity assessment 126

Section C: Quantitative gel electrophoresis

II.C.1. Introduction 128

II.C.2. Experimental 128

II.C.2.1. Instrumentation 128

II.C.2.2. Chemicals and reagents 128

II.C.2.3. Standards and samples 129

II.C.2.4. Electrophoretic conditions 129

II.C.2.5. Calibration and validation 130

II.C.2.6. Stability study 131

II.C.2.7. Application to pharmaceutical formulations 132

II.C.2.8. Biosimilarity assessment 132

II.C.3. Results and discussion 132

II.C.3.1. Method validation 132

II.C.3.2. Stability study 140

II.C.3.3. Application to pharmaceutical formulations 147

II.C.3.4. Biosimilarity assessment 152

Part III: Spectrophotometric techniques

Section A: Dynamic light scattering

III.A.1. Introduction 158

III.A.2. Experimental 158

III.A.2.1. Instrumentation 158

III.A.2.2. Chemicals and reagents 159

III.A.2.3. Standards and samples 159

III.A.2.4. Mehod conditions 159

III.A.2.5. Stability study 160

III.A.2.6. Application to pharmaceutical formulations 160

III.A.2.7. Biosimilarity assessment 160

III.A.3. Results and discussion 161

III.A.3.1. Stability study 163

III.A.3.2. Application to pharmaceutical formulations 167

III.A.3.3. Biosimilarity assessment 168

Section B: Bradford assay

III.B.1. Introduction 171

III.B.2. Experimental 171

III.B.2.1. Instrumentation 171

III.B.2.2. Chemicals and reagents 171

III.B.2.3. Standards and samples 172

III.B.2.4. Bradford assay conditions 172

III.B.2.5. Calibration and validation 172

III.B.2.6. Application to pharmaceutical formulations 174

III.B.3. Results and discussion 174

III.B.3.1. Method validation 174

III.B.3.2. Application to pharmaceutical formulations 181

Part IV: Receptor binding assay

IV.1. Introduction 183

IV.2. Experimental 183

IV.2.1. Instrumentation 183

IV.2.2. Chemicals and reagents 183

IV.2.3. Standards and samples 184

IV.2.4. Receptor binding assay conditions 184

IV.2.5. Method validation 184

IV.2.6. Stability study 186

IV.2.7. Biosimilarity assessment 186

IV.3. Results and discussion 187

IV.3.1. Method validation 187

IV.3.2. Stability study 192

IV.3.3. Biosimilarity assessment 193

Part V: General discussion …….……..195

References…….201

الملخص العربي……..218

List of Figures

Figure 1: Polyclonal antibodies are mixture of heterogenous antibodies while monoclonal antibodies show unique specificity against single epitope 4

Figure 2: The four-chain structure of an antibody. The basic unit is composed of two identical light (L) chains and two identical heavy (H) chains, which are held together by disulfide bonds to form a flexible Y shape 6

Figure 3: Schematic overview of types of Mabs. **A)** Murine monoclonal antibody. **B)** Chimeric monoclonal antibody **C)** Humanized monoclonal antibody **D)** Fully human monoclonal 8

Figure 4: CD20 is an integral membrane protein that crosses the cell membrane. Rituximab binds to CD20 via the Fab region through paratope-epitope interaction [34]. 10

Figure 5: Schematic presentation for biosimilar assessment program including physicochemical, biological characterization, preclinical studies, pharmacokinetics, pharmacodynamics and clinical trials 12

Figure 6: Mechanism of action of Rituximab and Obinutuzumab showing higher ADCC activity for obintuzumab 15

Figure 7: Chromatograms of SE-HPLC of a) RTX standard b) corresponding formulation buffer. 53

Figure 8: Chromatograms of SE-HPLC of a) OBZ standard b) corresponding formulation buffer. 54

Figure 9: Chromatograms of SE-HPLC of a) PTZ standard b) corresponding formulation buffer. 55

Figure 10: Chromatograms of SE-HPLC showing peak purity of a) RTX and OBZ standards, b) degraded samples incubated at 37℃ for 4 weeks.. 56